Route does appear to matter.

Oral estrogen is associated with a higher risk of blood clots and, to a lesser degree, stroke, most likely because it passes through the liver first and affects clotting factors. Transdermal estradiol (patches, gels) has not been linked to increased clot risk in any major observational study, and guidelines now recommend considering transdermal therapy for women at higher clotting risk, including those with a higher BMI. No randomized trial has been specifically designed to test clot risk by route, so this evidence is observational, though it is consistent across multiple large studies.

What to know about this answer

Almost everyone in the field agrees transdermal looks meaningfully safer for clotting; the caution is that this comes entirely from observational data, no trial has been powered specifically to test it, and even transdermal is not risk-free at high doses.

What the research shows, and which source each finding rests on

ESTHER study: venous clot odds ratio 3.5 for oral estrogen vs 0.9 for transdermal; oral vs transdermal directly, OR 4.0.

C[1]

ESTHER expanded: oral OR 4.2, transdermal OR 0.9; progestogen type mattered - micronized progesterone and pregnane derivatives were not associated with clot risk, while norpregnane derivatives carried OR 3.9.

B[2]

UK QResearch/CPRD nested case-control (80,396 clot cases): oral hormone therapy OR 1.58; CEE+MPA the highest at 2.10; transdermal overall OR 0.93, no increased risk - the authors call transdermal 'the safest type' and note it appears to be underused.

C[3]

UK GPRD nested case-control: current oral hormone therapy stroke rate ratio 1.28; transdermal overall 0.95; low-dose patches (50 mcg or less) 0.81; high-dose patches 1.89.

C[4]

NICE NG23 recommends considering transdermal rather than oral hormone therapy for people at increased risk of venous clots, including those with a BMI over 30.

A[5]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Transdermal is meaningfully safer, near-consensus

near-universal position among field clinicians in the corpus, increasingly reflected in guidelines

Every major case-control study shows no clot elevation for transdermal estrogen, there is a clear biological mechanism (no first-pass liver effect on clotting factors), and NICE guidance now codifies a preference for transdermal in higher-risk women; low-dose transdermal was also neutral for stroke.

C[1]B[2]C[3]C[4]A[5]

The safety data are observational, and dose still matters

a caution flagged directly in the source material

No randomized trial has been powered to test clot risk by route, so residual confounding is possible - clinicians may already be steering higher-risk women toward patches. And the stroke data show high-dose patches carried a rate ratio of 1.89, so transdermal is not categorically risk-free independent of dose.

C[4]

What would settle it: A randomized trial comparing routes with clotting and clinical endpoints, or large studies stratified specifically by clotting-disorder status.

What is really going on here

  1. Which regimen was studied - oral or transdermal - and which am I being prescribed?
  2. Given my BMI, clotting history, and migraine status, should I be on transdermal rather than oral estrogen?

Questions for your doctor

  1. Given my personal and family clotting history, BMI, and migraine status, is transdermal a better fit for me than oral?
  2. What dose am I on, and does the dose itself affect my stroke or clot risk?
  3. If I'm currently on oral estrogen, is there a reason not to switch to transdermal?

Questions with no answer yet

Is transdermal estrogen's apparently clean safety record on blood clots because it is genuinely safer, or because clinicians already tend to steer higher-clotting-risk women toward it, making the comparison unfair from the start?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No randomized trial has been powered to test clot risk by route. The reassuring transdermal data come entirely from observational studies, where residual confounding by indication, clinicians already channeling higher-risk women to patches, is possible, which could bias the comparison in either direction.

What would test it: A randomized trial comparing route with clotting and clinical endpoints, or large target-trial-emulation analyses with thrombophilia stratification built in from the start.

At what dose does transdermal estrogen stop being clot-neutral, given that high-dose patches showed an elevated stroke rate while low-dose patches did not?

Partly studied

What is known: One large nested case-control study found low-dose transdermal patches carried no increased stroke risk while high-dose patches carried a clearly elevated rate, showing that transdermal is not a single safety category independent of dose. Where exactly the risk begins to rise between those two doses has not been mapped.

What would test it: A dose-response analysis within transdermal users specifically, ideally using several intermediate doses rather than only a low and a high category.

Sources

  1. 1.Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.Scarabin PY, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk (ESTHER). Lancet. 2003;362(9382):428-32. · Observational study
  2. 2.Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens (ESTHER). Circulation. 2007;115(7):840-5. · Randomised trial
  3. 3.Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies (QResearch/CPRD). BMJ. 2019;364:k4810. · Observational study
  4. 4.Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.Renoux C, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519. · Observational study
  5. 5.NICE guideline NG23. Menopause: identification and management. November 2024 update, recommendation 1.5.27.Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions